Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 2
2008 6
2009 8
2010 10
2011 10
2012 12
2013 10
2014 6
2015 4
2016 4
2017 9
2018 5
2019 3
2021 6
2022 4
2023 4
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

91 results

Results by year

Filters applied: . Clear all
Page 1
Molecular profiling of patients with cytogenetically normal acute myeloid leukemia and hyperleukocytosis.
Pastore F, Pastore A, Rothenberg-Thurley M, Metzeler KH, Ksienzyk B, Schneider S, Bohlander SK, Braess J, Sauerland MC, Görlich D, Berdel WE, Wörmann B, von Bergwelt-Baildon MS, Hiddemann W, Spiekermann K. Pastore F, et al. Cancer. 2022 Dec 15;128(24):4213-4222. doi: 10.1002/cncr.34495. Epub 2022 Oct 22. Cancer. 2022. PMID: 36271776 Free article.
The aims of this study were to delineate the underlying molecular landscape in the largest cytogenetic risk group, cytogenetically normal acute myeloid leukemia (CN-AML), and to assess the prognostic relevance of recurrent mutations in the conte …
The aims of this study were to delineate the underlying molecular landscape in the largest cytogenetic risk group, cytogenetically …
Molecular prognostic factors in cytogenetically normal acute myeloid leukemia.
Walker A, Marcucci G. Walker A, et al. Expert Rev Hematol. 2012 Oct;5(5):547-58. doi: 10.1586/ehm.12.45. Expert Rev Hematol. 2012. PMID: 23146058 Free PMC article. Review.
Chromosomal abnormalities are detected in 50-60% of patients with acute myeloid leukemia (AML) and are important predictors of prognosis and risk of relapse. The remaining patients, those with cytogenetically normal AML, are a seemingly homogeneous group that in fact consi …
Chromosomal abnormalities are detected in 50-60% of patients with acute myeloid leukemia (AML) and are important predictors of progno …
IDH mutations in acute myeloid leukemia.
Rakheja D, Konoplev S, Medeiros LJ, Chen W. Rakheja D, et al. Hum Pathol. 2012 Oct;43(10):1541-51. doi: 10.1016/j.humpath.2012.05.003. Epub 2012 Aug 20. Hum Pathol. 2012. PMID: 22917530 Review.
IDH1/IDH2 mutations are heterozygous, and their combined frequency is approximately 17% in unselected acute myeloid leukemia cases, 27% in cytogenetically normal acute myeloid leukemia cases, and up to 67% in acute myeloid leukemia cases with cu …
IDH1/IDH2 mutations are heterozygous, and their combined frequency is approximately 17% in unselected acute myeloid leukemia cases, 27% in …
Prognostically important molecular markers in cytogenetically normal acute myeloid leukemia.
Lin TL, Smith BD. Lin TL, et al. Am J Med Sci. 2011 May;341(5):404-8. doi: 10.1097/MAJ.0b013e318201109d. Am J Med Sci. 2011. PMID: 21522052 Free PMC article. Review.
Cytogenetically normal acute myeloid leukemia (CN-AML) is a heterogeneous disease with variable clinical outcomes. ...In this article, the authors discuss the classical clinical features of AML and the importance of cytogenetics that predict …
Cytogenetically normal acute myeloid leukemia (CN-AML) is a heterogeneous disease with variable clinical …
The Prognostic Significance of PDE7B in Cytogenetically Normal Acute Myeloid Leukemia.
Cao L, Zhang W, Liu X, Yang P, Wang J, Hu K, Zhang X, Liu W, He X, Jing H, Yuan X. Cao L, et al. Sci Rep. 2019 Nov 18;9(1):16991. doi: 10.1038/s41598-019-53563-x. Sci Rep. 2019. PMID: 31740742 Free PMC article.
We have tried to find some significant molecular markers for this part of the cytogenetic normal AML, which hopes to provide a benefit for the diagnosis, molecular typing and prognosis prediction of AML patients. In the present study, we calculated and compared the gene ex …
We have tried to find some significant molecular markers for this part of the cytogenetic normal AML, which hopes to provide a benefit for t …
A novel 5-gene prognostic signature to improve risk stratification of cytogenetically normal acute myeloid leukemia.
Deng C, Zeng T, Zhu P, Zhao S, Huang Z, Huang W, Zhang W, Huang X, Fu L. Deng C, et al. J Cancer Res Clin Oncol. 2023 Sep;149(12):10015-10025. doi: 10.1007/s00432-023-04884-y. Epub 2023 Jun 1. J Cancer Res Clin Oncol. 2023. PMID: 37258721
PURPOSE: Prognostic prediction is a challenging task in cytogenetically normal acute myeloid leukemia (CN-AML) patients. ...Nomogram including the 5-gene risk score performed well in predicting 1-year, 2-year and 3-year OS. …
PURPOSE: Prognostic prediction is a challenging task in cytogenetically normal acute myeloid leukemia …
Prognostic and Biologic Relevance of Clinically Applicable Long Noncoding RNA Profiling in Older Patients with Cytogenetically Normal Acute Myeloid Leukemia.
Papaioannou D, Nicolet D, Ozer HG, Mrózek K, Volinia S, Fadda P, Carroll AJ, Kohlschmidt J, Kolitz JE, Wang ES, Stone RM, Byrd JC, Garzon R, Bloomfield CD. Papaioannou D, et al. Mol Cancer Ther. 2019 Aug;18(8):1451-1459. doi: 10.1158/1535-7163.MCT-18-1125. Epub 2019 Jun 4. Mol Cancer Ther. 2019. PMID: 31164409 Free PMC article.
We have previously shown that expression levels of 48 long noncoding RNAs (lncRNA) can generate a prognostic lncRNA score that independently associates with outcome of older patients with cytogenetically normal acute myeloid leukemia (CN- …
We have previously shown that expression levels of 48 long noncoding RNAs (lncRNA) can generate a prognostic lncRNA score that indepe …
Prognostic impact of PRDM16 expression in acute myeloid leukemia with normal cytogenetics.
Xiang X, Lu Q, Xu X, Cai P, Chen S, Pan J, Zeng Z. Xiang X, et al. Hematology. 2022 Dec;27(1):499-505. doi: 10.1080/16078454.2022.2066306. Hematology. 2022. PMID: 35473465

PURPOSE: Cytogenetically normal acute myeloid leukemia (CN-AML) is a heterogeneous disease with variable clinical outcomes. ...In addition, PRDM16 expression was significantly correlated with WT1 expression in CN-AML (r = 0.7, p < 0.001). The

…
PURPOSE: Cytogenetically normal acute myeloid leukemia (CN-AML) is a heterogeneous disease with variable …
MiR-362-5p as a novel prognostic predictor of cytogenetically normal acute myeloid leukemia.
Ma QL, Wang JH, Yang M, Wang HP, Jin J. Ma QL, et al. J Transl Med. 2018 Mar 14;16(1):68. doi: 10.1186/s12967-018-1445-3. J Transl Med. 2018. PMID: 29540187 Free PMC article.
The Cox regression analyses were carried out to assess the prognostic significance of miR-362-5p expression in the context of the well-established predictors. Additionally, microRNA expression profiling were conducted to identify the biological insights between high and lo …
The Cox regression analyses were carried out to assess the prognostic significance of miR-362-5p expression in the context of the well-estab …
Hh/Gli antagonist in acute myeloid leukemia with CBFA2T3-GLIS2 fusion gene.
Masetti R, Bertuccio SN, Astolfi A, Chiarini F, Lonetti A, Indio V, De Luca M, Bandini J, Serravalle S, Franzoni M, Pigazzi M, Martelli AM, Basso G, Locatelli F, Pession A. Masetti R, et al. J Hematol Oncol. 2017 Jan 21;10(1):26. doi: 10.1186/s13045-017-0396-0. J Hematol Oncol. 2017. PMID: 28109323 Free PMC article.
BACKGROUND: CBFA2T3-GLIS2 is a fusion gene found in 17% of non-Down syndrome acute megakaryoblastic leukemia (non-DS AMKL, FAB M7) and in 8% of pediatric cytogenetically normal acute myeloid leukemia (CN-AML, in association with several French-A …
BACKGROUND: CBFA2T3-GLIS2 is a fusion gene found in 17% of non-Down syndrome acute megakaryoblastic leukemia (non-DS AMKL, FAB M7) and in 8% …
91 results